So even if J&J’s shot does prove significantly more durable, that advantage would be weighed against other factors.
In December, the CDC recommended that Americans opt for mRNA vaccines over J&J’s, because those shots showed higher effectiveness and fewer rare, serious side effects. "That’s eight-plus months, so that’s a long time," Atmar said.Įxperts expect conversations about vaccine durability to remain in the spotlight as the coronavirus transitions to an endemic state.īut even as the picture gets clearer, Corey said, risk-benefit analyses will differ from person to person. The median number of days after the second dose for those patients was 256. “I’m not an infectious disease physician, but in my mind as a consumer, as somebody who’s getting vaccinated … if you have a choice of equally efficacious vaccines, or almost equally efficacious, and one you get boosted in much larger intervals, I would prefer that," Schneeweiss said.Ītmar pointed to a CDC study published Friday, which found that among people who got two doses of an mRNA vaccine - no booster - effectiveness at preventing mechanical ventilation and death from an omicron infection was 79 percent through Jan. Studying durability, of course, is crucial in determining whether booster shots are needed, and when. "The J&J vaccine raises antibody responses that are much lower initially and protection that is slightly lower initially, but both of those appear to be more maintained over time." "The mRNA vaccines raise antibody responses very high very quickly, and then those antibody responses and protection decline quickly, necessitating multiple rounds of boosting," said Barouch, who helped develop and study the J&J vaccine. Centers for Disease Control and Prevention, indicating the Johnson & Johnson Covid-19 vaccine provides durable protection against breakthrough infection, Covid-19-related hospitalization and death."ĭan Barouch, director of the Center for Virology and Vaccine Research at Boston’s Beth Israel Deaconess Medical Center, thinks a clearer picture is emerging of the Covid vaccines' differing properties. "We also are not saying it’s limited to 180 days," he said, noting that was just the data available, which came from insurance claims.Ī spokesperson at Janssen, J&J’s pharmaceutical arm, said in a statement that "the results add to a growing body of evidence, including provisional data from the U.S.
0 kommentar(er)
